CD274 and non-small cell lung carcinoma: Although not FDA approved, it is worthwhile to mention that the PD-L1 inhibitor durvalumab was recently granted FDA breakthrough designation in the adjuvant treatment of locally advanced, unresectable NSCLC based on the phase III PACIFIC trial [31].